Acute promyelocytic leukemia current treatment algorithms

por Yilmaz, Musa, Kantarjian, Hagop, Ravandi, Farhad
Publicado 2021

Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia

por Hein, Kyaw, Short, Nicholas, Jabbour, Elias, Yilmaz, Musa
Publicado 2022

Serum ghrelin and obestatin levels in patients with acne vulgaris: are they important for the severity?

por Kanat, Zekiye, Kökçam, İbrahim, Yılmaz, Musa, Aydın, Süleyman, Özkan, Zeynep
Publicado 2019

The cardiovascular system and the biochemistry of grafts used in heart surgery

por Aydin, Suna, Aydin, Suleyman, Eren, Mehmet Nesimi, Sahin, İbrahim, Yilmaz, Musa, Kalayci, Mehmet, Gungor, Orhan
Publicado 2013

Brain, Liver, and Serum Salusin-alpha and -beta Alterations in Sprague-Dawley Rats with or without Metabolic Syndrome

por Citil, Cihan, Konar, Vahit, Aydin, Suleyman, Yilmaz, Musa, Albayrak, Serdal, Ozercan, Ibrahim Hanifi, Ozkan, Yusuf
Publicado 2014

Acylated and Desacylated Ghrelin, Preptin, Leptin, and Nesfatin-1 Peptide Changes Related to the Body Mass Index

por Ozkan, Yusuf, Timurkan, Esra Suay, Aydin, Suleyman, Sahin, İbrahim, Timurkan, Mustafa, Citil, Cihan, Kalayci, Mehmet, Yilmaz, Musa, Aksoy, Aziz, Catak, Zekiye
Publicado 2013

P672: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES

por Bidikian, Aram, Haddad, Fadi, Sasaki, Koji, Issa, Ghayas, Kadia, Tapan, Jain, Nitin, Alvarado, Yesid, Short, Nicholas, Yilmaz, Musa, Masarova, Lucia, Jabbour, Elias, Kantarjian, Hagop
Publicado 2023

Adropin as a potential marker of enzyme-positive acute coronary syndrome

por Aydin, Suna, Eren, Mehmet Nesimi, Yilmaz, Musa, Yardim, Meltem, Aydin, Suleyman, Kalayci, Mehmet, Alatas, Omer Dogan, Kuloglu, Tuncay, Balaban, Heseyin, Cakmak, Tolga, Kobalt, Mehmet Ali, Çelik, Ahmet
Publicado 2017

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series

por Alotaibi, Ahmad S., Yilmaz, Musa, Loghavi, Sanam, DiNardo, Courtney, Borthakur, Gautam, Kadia, Tapan M., Thakral, Beenu, Pemmaraju, Naveen, Issa, Ghayas C., Konopleva, Marina, Short, Nicholas J., Patel, Keyur, Tang, Guilin, Ravandi, Farhad, Daver, Naval
Publicado 2020

P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUD...

por Short, Nicholas, Jabbour, Elias, Jain, Nitin, Haddad, Fadi, Yilmaz, Musa, Nasr, Lewis, Ferrajoli, Alessandra, Kadia, Tapan, Alvarado, Yesid, Maiti, Abhishek, Macaron, Walid, Zoghbi, Marianne, Nasnas, Cedric, Garris, Rebecca, Zhao, Min, Konopleva, Marina, Ravandi, Farhad, Kantarjian, Hagop
Publicado 2023

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

por Saxena, Kapil, Jabbour, Elias, Issa, Ghayas, Sasaki, Koji, Ravandi, Farhad, Maiti, Abhishek, Daver, Naval, Kadia, Tapan, DiNardo, Courtney D., Konopleva, Marina, Cortes, Jorge E., Yilmaz, Musa, Chien, Kelly, Pierce, Sherry, Kantarjian, Hagop, Short, Nicholas J.
Publicado 2021

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia

por Ravandi, Farhad, Bashey, Asad, Foran, James, Stock, Wendy, Mawad, Raya, Short, Nicholas, Yilmaz, Musa, Kantarjian, Hagop, Odenike, Olatoyosi, Patel, Anand, Garcha, Raman, Ainsworth, William Barrett, Clynes, Raphael, Kanodia, Jitendra, Ding, Ying, Li, Huajiang, Kye, Steve, Mims, Alice
Publicado 2023

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

por Abbas, Hussein A., Sun, Hanxiao, Pierce, Sherry, Kanagal-Shamanna, Rashmi, Li, Ziyi, Yilmaz, Musa, Borthakur, Gautam, DiPippo, Adam J., Jabbour, Elias, Konopleva, Marina, Short, Nicholas J., DiNardo, Courtney, Daver, Naval, Ravandi, Farhad, Kadia, Tapan M.
Publicado 2022

P364: A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE L...

por Haddad, Fadi, Jabbour, Elias, Nasr, Lewis, Short, Nicholas, Macaron, Walid, Nasnas, Cedric, Zoghbi, Marianne, Issa, Ghayas, Yilmaz, Musa, Daver, Naval, Pemmaraju, Naveen, Masarova, Lucia, Ravandi, Farhad, Jain, Nitin, Deen, Wuliamatu, Loiselle, Christopher, Waller, Lourdes, Banks, Glenda, Garris, Rebecca, Kantarjian, Hagop
Publicado 2023

P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND

por Nguyen, Daniel, Kantarjian, Hagop, Bidikian, Aram, Dinardo, Courtney, Kadia, Tapan, Daver, Naval, Borthakur, Gautam, Jabbour, Elias, Yilmaz, Musa, Short, Nicholas, Maiti, Abhishek, Sasaki, Koji, Montalban-Bravo, Guillermo, Hammond, Danielle, Pierce, Sherry, Andreeff, Michael, Garcia-Manero, Guillermo, Ravandi, Farhad, Issa, Ghayas
Publicado 2023

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?

por Yilmaz, Musa, Wang, Feng, Loghavi, Sanam, Bueso-Ramos, Carlos, Gumbs, Curtis, Little, Latasha, Song, Xingzhi, Zhang, Jianhua, Kadia, Tapan, Borthakur, Gautam, Jabbour, Elias, Pemmaraju, Naveen, Short, Nicholas, Garcia-Manero, Guillermo, Estrov, Zeev, Kantarjian, Hagop, Futreal, Andrew, Takahashi, Koichi, Ravandi, Farhad
Publicado 2019

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

por Samra, Bachar, Richard-Carpentier, Guillaume, Kadia, Tapan M., Ravandi, Farhad, Daver, Naval, DiNardo, Courtney D., Issa, Ghayas C., Bose, Prithviraj, Konopleva, Marina Y., Yilmaz, Musa, Ohanian, Maro, Borthakur, Gautam, Garcia-Manero, Guillermo, Pierce, Sherry, Cortes, Jorge E., Kantarjian, Hagop, Short, Nicholas J.
Publicado 2020

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

por Venugopal, Sangeetha, Takahashi, Koichi, Daver, Naval, Maiti, Abhishek, Borthakur, Gautam, Loghavi, Sanam, Short, Nicholas. J., Ohanian, Maro, Masarova, Lucia, Issa, Ghayas, Wang, Xuemei, Carlos, Bueso-Ramos, Yilmaz, Musa, Kadia, Tapan, Andreeff, Michael, Ravandi, Farhad, Konopleva, Marina, Kantarjian, Hagop M., DiNardo, Courtney D.
Publicado 2022

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS

por Bazinet, Alexandre, Arani, Naszrin, Chien, Kelly, Hammond, Danielle, Kadia, Tapan, Borthakur, Gautam, Alvarado, Yesid, Sasaki, Koji, Dinardo, Courtney, Pemmaraju, Naveen, Masarova, Lucia, Short, Nicholas, Yilmaz, Musa, Daver, Naval, Jabbour, Elias, Ravandi, Farhad, Kanagal-Shamanna, Rashmi, Pierce, Sherry, Kantarjian, Hagop, Garcia-Manero, Guillermo, Montalban-Bravo, Guillermo
Publicado 2023

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia

por Kantarjian, Hagop, Haddad, Fadi G., Jain, Nitin, Sasaki, Koji, Short, Nicholas J., Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Jorgensen, Jeffrey, Khouri, Issa, Kebriaei, Partow, Alvarado, Yesid, Kadia, Tapan, Paul, Shilpa, Garcia-Manero, Guillermo, Dabaja, Bouthaina, Yilmaz, Musa, Jacob, Jovitta, Garris, Rebecca, O’Brien, Susan, Ravandi, Farhad, Jabbour, Elias
Publicado 2023